Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

Widely established targeted therapies directed at triple negative breast cancer (TNBC) are missing. Classical chemotherapy remains the systemic treatment option. Cisplatin has been tested in TNBC but bears the disadvantage of resistance development. | Inhibition of PI3K Akt mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN